Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

US FDA Grants Approval for LBT's APAS®

LBT Innovations Limited
Posted on: 10 Oct 16

PR Newswire

ADELAIDE, Australia, Oct.10, 2016

ADELAIDE, Australia, Oct.10, 2016 /PRNewswire/ -- Clever Culture Systems AG (CCS), the Swiss based joint venture between Australian medical technology company LBT  Innovations Limited (ASX:  LBT) and Hettich AG (Switzerland) has received clearance of its 510(k) de novosubmission to the US Food and Drug Administration (FDA) for APAS® as a Class II medical device.

APAS® (Automated Plate Assessment System) is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. APAS ® enables the faster diagnosis and reporting of infectious diseases.

Developed by LBT Innovations, APAS® has been licensed on a global, exclusive basis to CCS, which is integrating APAS with laboratory robotic instrumentation. CCS is targeting to bring APAS to market in 2017 as an automated stand-alone plate reader (APAS ® Independence) followed by the integrated incubator (APAS® Incubot).

The 510(k) de novo submission used a manual version of APAS to test 10,000 patients in a series of clinical trials conducted in Australia and the US over a 12-month period. In each trial, APAS achieved its target primary endpoints and the results matched or exceeded the findings of a panel of experienced microbiologists.

Mr Brent Barnes, CEO of LBT Innovations, said, "FDA clearance follows rigorous interrogation and validation of the capabilities of APAS. The successful clinical trial program completed in 2015 and clearance by FDA also validate the underlying technology that is the core platform of our Company's vision to integrate imaging with interpretative intelligence to deliver faster and more secure diagnoses for patients. FDA clearance is a fitting tribute tothe many years of painstaking work by LBT's staff and partners, who together have made our shared vision a reality."

Mrs Lusia Guthrie (recently retired LBT CEO and Chairman of CCS), confirmed that CCS is in continuing discussions with significant global diagnostics companies for the licensing of the APAS product portfolio, including APAS Independence and APAS Incubot, plus  flow-on product opportunities on the drawing board all aimed at the clinical microbiology laboratory.

About LBT Innovations

LBT  Innovations  (LBT)  is  an  Australian  developer  of clinical  and  diagnostic  technology.  Based in Adelaide, South Australia, the Company has two class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and APAS®.  Based  on  LBT's innovative  intelligent  image  interpretative  platform,  APAS®  specifically  addresses  the  automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich AG Switzerland to drive the commercialisation of APAS® products.  LBT also has a third product in early development, WoundVue®, a proposed automated solution to assist in the management of chronic wounds.

For more information, see


LBT Innovations Media Relations
Brent Barnes CEO & MD
Tel: +61 (0)8 8227 1555 or Mobile 0409 677 654

Rudi Michelson - Monsoon Communications
Tel: +61 (0)3 9620 3333 or Mobile 0411 402 737

To view the original version on PR Newswire, visit:

SOURCE LBT Innovations Limited

PR Newswire

Last updated on: 10/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.